BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26872652)

  • 1. Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
    Ceppi F; Weitzman S; Woessmann W; Davies K; Lassaletta A; Reismüller B; Mellgren K; Uyttebroeck A; Maia I; Abdullah S; Miakova N; Glaser D; Cohn R; Abla O; Attarbaschi A; Alexander S
    Am J Hematol; 2016 May; 91(5):486-91. PubMed ID: 26872652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
    Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
    Maury S; Chevret S; Thomas X; Heim D; Leguay T; Huguet F; Chevallier P; Hunault M; Boissel N; Escoffre-Barbe M; Hess U; Vey N; Pignon JM; Braun T; Marolleau JP; Cahn JY; Chalandon Y; Lhéritier V; Beldjord K; Béné MC; Ifrah N; Dombret H;
    N Engl J Med; 2016 Sep; 375(11):1044-53. PubMed ID: 27626518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.
    Pels H; Schulz H; Schlegel U; Engert A
    Onkologie; 2003 Aug; 26(4):351-4. PubMed ID: 12972702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.
    Claviez A; Eckert C; Seeger K; Schrauder A; Schrappe M; Henze G; von Stackelberg A
    Haematologica; 2006 Feb; 91(2):272-3. PubMed ID: 16461321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
    Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Effect of CD20 Expression in Adult B-cell Acute Lymphoblastic Leukemia.
    Esteban RE; Christianne B; Alvaro A; Demichelis-Gómez R
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):361-367. PubMed ID: 29544762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
    Meinhardt A; Burkhardt B; Zimmermann M; Borkhardt A; Kontny U; Klingebiel T; Berthold F; Janka-Schaub G; Klein C; Kabickova E; Klapper W; Attarbaschi A; Schrappe M; Reiter A;
    J Clin Oncol; 2010 Jul; 28(19):3115-21. PubMed ID: 20516455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optic nerve relapse in a child with common acute lymphoblastic leukemia, treated with systemic anti-CD-20 (rituximab).
    Kraal K; Schalij-Delfos N; van Buchem M; Egeler M; Ball L
    Haematologica; 2005 Nov; 90 Suppl():ECR24. PubMed ID: 16266915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).
    Oertel SH; Verschuuren E; Reinke P; Zeidler K; Papp-Váry M; Babel N; Trappe RU; Jonas S; Hummel M; Anagnostopoulos I; Dörken B; Riess HB
    Am J Transplant; 2005 Dec; 5(12):2901-6. PubMed ID: 16303003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
    Eberle FC; Holstein J; Scheu A; Fend F; Yazdi AS
    J Dtsch Dermatol Ges; 2017 Mar; 15(3):319-323. PubMed ID: 28177583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
    Robak T
    Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma.
    Antonini G; Cox MC; Montefusco E; Ferrari A; Conte E; Morino S; Latino P; Trasimeni G; Monarca B
    J Neurooncol; 2007 Jan; 81(2):197-9. PubMed ID: 16937012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab.
    Pels H; Schulz H; Manzke O; Hom E; Thall A; Engert A
    J Neurooncol; 2002 Sep; 59(3):213-6. PubMed ID: 12241117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of CD20-positive Adult B-cell Acute Lymphoblastic Leukemia and the Impact of Rituximab Therapy.
    Alduailej H; Kanfar S; Bakhit K; Raslan H; Alsaber A; Bashawri L; Aldayel A; Alanezi K
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e560-e568. PubMed ID: 32600932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system.
    van de Glind G; de Graaf S; Klein C; Cornelissen M; Maecker B; Loeffen J
    Pediatr Blood Cancer; 2008 Apr; 50(4):886-8. PubMed ID: 17668865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.
    Cook RC; Connors JM; Gascoyne RD; Fradet G; Levy RD
    Lancet; 1999 Nov; 354(9191):1698-9. PubMed ID: 10568575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.